Relmada Therapeutics, Inc. (RLMD) 주식 분석

회사 개요

Relmada Therapeutics, Inc. (RLMD) operates as a clinical-stage biotechnology firm located in the United States, with its primary strategic focus on the development of NDV-01, a controlled-release intravesical formulation combining gemcitabine and docetaxel for treating aggressive forms of non-muscle invasive bladder cancer. The company functions within the broader Healthcare sector, specifically targeting the Biotechnology industry, which typically involves high levels of research and development risk while seeking breakthrough therapies for specific disease states. As of the latest available data, the enterprise holds a market capitalization of $733.18M and employs a workforce of 17 individuals, indicating a highly specialized and lean operational structure common in early-stage biotech development. The combination of a market cap exceeding $700 million with a revenue base classified as N/A suggests that the company's valuation is driven primarily by asset potential and clinical trial progress rather than current earnings generation, positioning it as a capital-intensive entity reliant on future commercialization success rather than immediate cash flow from sales.

재무 건전성

Relmada Therapeutics reported a net income of $-15,005,199 over the trailing twelve months, while its EBITDA stands at $-13,855,048, highlighting a significant operational loss that is typical for clinical-stage companies investing heavily in R&D. The disparity between the reported net income and EBITDA, alongside a free cash flow of $-7,737,662, reveals a cost structure where operating expenses and cash burn rates substantially exceed current revenue generation, which is currently N/A. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that indicates the company has not yet generated sufficient sales to cover its fixed costs and create a positive bottom line. Despite the absence of current profitability, the balance sheet maintains $116.44M in cash against a debt obligation of $110,247, resulting in a debt-to-equity ratio of 0.10, which demonstrates a highly conservative capital structure with minimal leverage. The current ratio is reported at 80.21, a metric that signals robust short-term liquidity as the company's current assets vastly exceed its current liabilities, providing ample buffer to fund ongoing clinical trials. Furthermore, the return on equity is -25.6% and the return on assets is -14.4%, metrics that reflect the dilution of shareholder and asset value due to accumulated losses rather than ineffective management, as these negative returns are inherent to the pre-revenue stage of the business lifecycle.

밸류에이션 평가

The valuation metrics for Relmada Therapeutics present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is calculated at -17.05, implying that analysts do not expect immediate positive earnings to drive valuation multiples. The price-to-book ratio sits at 5.92, suggesting that the market values the company at nearly six times its book value, which may reflect investor optimism regarding the potential success of the NDV-01 clinical trial rather than current tangible asset value. Alternative valuation measures such as the price-to-sales ratio are classified as N/A, and the EV/EBITDA multiple is 2.65, which is an unusually low figure for a company with negative earnings, indicating that the enterprise value is calculated primarily based on equity value without significant debt adjustments. Regarding price volatility, the stock has traded between a 52-week low of $0.24 and a high of $7.51, meaning the current market price is trading significantly below the annual peak but well above the recent trough. The beta value is listed as N/A, which prevents a direct comparison of the stock's volatility relative to the broader market index, though the wide range between the high and low suggests substantial price fluctuations typical of small-cap biotechnology stocks.

Growth & Income

Relmada Therapeutics currently reports revenue growth and earnings growth rates as N/A, as the company has not yet achieved the consistent commercial sales required to calculate year-over-year percentage changes in these fundamental metrics. Since the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute any dividends to shareholders, a strategy consistent with firms that must retain all capital to finance expensive clinical trials and regulatory submissions. This absence of a dividend payout indicates that the firm reinvests all available cash flow, including its $116.44M cash reserve, directly back into its research and development pipeline rather than returning capital to investors. Consequently, the overall growth and income profile for Relmada Therapeutics is characterized by zero current income generation and a growth trajectory that is entirely dependent on the successful advancement of its pipeline assets through Phase 2 clinical trials into later stages of development.